The treatment of children suffering from chronic myelogenous leukemia: A comparison of the result of treatment with imatinib mesylate and allogeneic hematopoietic stem cell transplantation

Pediatric Transplantation

Volumn 17, Issue 4, 2013, Pages 380-386

  Hamidieh, Amir Ali ^a   Ansari, Shahla ^b   Darbandi, Bahram ^b   Soroush, Alborz ^c   Arjmandi Rafsanjani, Khadijeh ^b   Alimoghaddam, Kamran ^a   Bahosh, Gholamreza ^b   Behfar, Maryam ^a   Ghavamzadeh, Ardeshir ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

children; chronic myeloid leukemia; hematopoietic stem cell transplantation; imatinib

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; GANCICLOVIR; HLA A ANTIGEN; HLA B ANTIGEN; HYDROXYUREA; IMATINIB; METHOTREXATE;

ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTHRALGIA; ARTICLE; BONE MARROW BIOPSY; BONE PAIN; CANCER MORTALITY; CHILD; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MONITORING; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEALTH SURVEY; HISTOCOMPATIBILITY; HISTOPATHOLOGY; HUMAN; LEUKEMIA RELAPSE; MALE; MOLECULAR TYPING; MYALGIA; MYCOSIS; NEUTROPHIL; OVERALL SURVIVAL; PATIENT REFERRAL; PNEUMOCYSTOSIS; RARE DISEASE; RASH; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL RATE; THROMBOCYTE; TREATMENT DURATION; VIRUS INFECTION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84878015011     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12074     Document Type: Article

References (44)

1. Fialkow PJ, Jacobson RJ, Papayannopoulou T,. Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977: 63: 125-130.
2. Fialkow PJ, Gartler SM, Yoshida A,. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA 1967: 58: 1468-1471.
3. Sugawara W, Endo M, Nakatuji Y, et al. Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia. Rinsho Ketsueki 2003: 44: 962-964.
4. Altman AJ,. Chronic leukemias of childhood. Pediatr Clin North Am 1988: 35: 765-787.
5. Cortes JE, Talpaz M, Kantarjian H,. Chronic myelogenous leukemia: A review. Am J Med 1996: 100: 555-570.
6. Cwynarski K, Roberts IA, Iacobelli S, et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003: 102: 1224-1231.
7. Bittencourt H, Funke V, Fogliatto L, et al. Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. Bone Marrow Transplant 2008: 42: 597-600.
8. Shenoy S, Smith FO,. Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin. Bone Marrow Transplant 2008: 41: 141-148.
9. Moen MD, McKeage K, Plosker GL, et al. Imatinib: A review of its use in chronic myeloid leukaemia. Drugs 2007: 67: 299-320.
10. Krol L, Formankova R, Keslova P, et al. Prognosis of pediatric patients transplanted for Ph+ chronic myeloid leukemia in the period from 1989 to 2006 in the Czech Republic. Neoplasma 2008: 55: 101-106.
11. Mauro MJ, Druker BJ,. Chronic myelogenous leukemia. Curr Opin Oncol 2001: 13: 3-7.
12. Druker BJ, Lydon NB,. Lessons learned from the development of an ABL tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000: 105: 3-7.
13. Deininger MW, Goldman JM, Melo JV,. The molecular biology of chronic myeloid leukemia. Blood 2000: 96: 3343-3356.
14. FDA approves gleevec for leukemia treatment. FDA Consum 2001: 35: 6.
15. FDA approves gleevec for pediatric leukemia. FDA Consum 2003: 37: 6.
16. Clift RA, Appelbaum FR, Thomas ED,. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993: 82: 1954-1956.
17. Davies SM, Defor TE, McGlave PB, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001: 110: 339-346.
18. Dini G, Rondelli R, Miano M, et al. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children: Experience of eight european countries. The EBMT paediatric diseases working party. Bone Marrow Transplant 1996: 18 (Suppl 2): 80-85.
19. Gamis AS, Haake R, McGlave P, et al. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. J Clin Oncol 1993: 11: 834-838.
20. Apperley JF, Jones L, Hale G, et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986: 1: 53-66.
21. Unal S, Fidan G, Tavil B, et al. Allogeneic hematopoietic stem cell transplantation in pediatric chronic myelogenous leukemia cases: Hacettepe experience. Pediatr Transplant 2007: 11: 645-649.
22. Kolb EA, Pan Q, Ladanyi M, et al. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. Cancer 2003: 98: 2643-2650.
23. Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008: 111: 1039-1043.
24. Thavaraj V, Seth R,. Imatinib mesylate, a new drug for chronic myeloid leukemia in pediatric patients. World J Pediatr 2007: 3: 110-114.
25. El-Alfy MS, Al-Haddad AM, Hamed AA,. Management of CML in the pediatric age group: Imatinib mesylate or SCT. J Egypt Natl Canc Inst 2010: 22: 227-232.
26. Suttorp M, Millot F,. Treatment of pediatric chronic myeloid leukemia in the year 2010: Use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology Am Soc Hematol Educ Program 2010: 2010: 368-376.
27. Rastogi MV, Stork L, Druker B, et al. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatr Blood Cancer 2012: 59: 840-845.
28. Bansal D, Shava U, Varma N, et al. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer 2012: 59: 481-484.
29. Speck B, Bortin MM, Champlin R, et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1984: 1: 665-668.
30. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974: 18: 295-304.
31. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002: 346: 645-652.
32. Andolina JR, Neudorf SM, Corey SJ,. How I treat childhood CML. Blood 2012: 119: 1821-1830.
33. Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (sti571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003: 9: 160-166.
34. Rhee Fv, Lin F, Cullis J, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994: 83: 3377-3383.
35. Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results. An analysis by the chronic leukemia working party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006: 91: 513-521.
36. Oyekunle A, Klyuchnikov E, Ocheni S, et al. Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematol 2011: 126: 30-39.
37. Lee JW, Chung NG,. The treatment of pediatric chronic myelogenous leukemia in the imatinib era. Korean J Pediatr 2011: 54: 111-116.
38. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (sti571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a children's oncology group phase 1 study. Blood 2004: 104: 2655-2660.
39. Muramatsu H, Takahashi Y, Sakaguchi H, et al. Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era. Int J Hematol 2011: 93: 186-191.
40. Alimoghaddam K, Ghavamzadeh A, Jahani M, et al. Hematopoietic stem cell transplantation in acute promyelocytic leukemia, experience in Iran. Arch Iran Med 2011: 14: 332-334.
41. Hamidieh AA, Alimoghaddam K, Jahani M, et al. Long-term results of non-fludarabine versus fludarabine-based stem cell transplantation without total body irradiation in Fanconi anemia patients. Hematol Oncol Stem Cell Ther 2011: 4: 109-115.
42. Hamidieh A, Kargar M, Jahani M, et al. The outcome of allogeneic hematopoietic stem cell transplants without total body irradiation in pediatric patients with acute lymphoblastic leukemia: Single centre experience. J Pediatr Hematol Oncol 2012: 34: 101-107.
43. Aschan J,. Risk assessment in haematopoietic stem cell transplantation: Conditioning. Best Pract Res Clin Haematol 2007: 20: 295-310.
44. Suttorp M, Yaniv I, Schultz KR,. Controversies in the treatment of CML in children and adolescents: TKIs versus BMT? Biol Blood Marrow Transplant 2011: 17: S115-S122.